Clinical trial of CA002 peanut allergy immunotherapy in children

A daily spoonful of a specially formulated peanut protein powder could protect over 200 children from severe allergic reactions within 12 weeks. Peanut allergy is the most common cause of severe food allergy reactions and deaths in children and adults. Constant vigilance to avoid accidental exposure profoundly reduces quality of life for sufferers and their families. Current management relies on avoidance and emergency medication, with no approved treatment that rapidly builds lasting protection. Camallergy’s drug CA002 works by gradually desensitising patients to increasing amounts of peanut proteins through seven short clinic visits followed by two years of daily home administration. An early access programme at the Cambridge Peanut Allergy Clinic has already achieved over 95% success in more than 200 children. This Phase 3 clinical trial across the UK and Ireland aims to confirm those results and position CA002 for regulatory approval in children and adults. If successful, the treatment would transform daily life for millions—allowing children to eat school meals, attend parties, and travel without constant fear. For families, it could replace a lifetime of label-checking and adrenaline-pen carrying with a simple daily routine.